Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Crow's Feet Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of a Dietary Supplement on Parameters of Skin Aging in Men and Women

NCT06083402
View directory record Official record
Conditions
Skin Aging
Interventions
HyaCera™, Placebo
Dietary Supplement
Lead sponsor
Natals, Inc. dba Ritual
Industry
Eligibility
25 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

NCT02176356
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
Interventions
onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC
Biological · Drug · Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

NCT04985916
View directory record Official record
Conditions
Lateral Canthal Lines, LCL, Crow's Feet
Interventions
Vehicle, botulinum toxin, Type A
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
19
States / cities
Scottsdale, Arizona • San Diego, California • Aventura, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

NCT03911102
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
DaxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sacramento, California • Sarasota, Florida • Itasca, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968942
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate ANT-1401 in Crow's Feet

NCT01809964
View directory record Official record
Conditions
Lateral Canthal Lines, Crows Feet
Interventions
ANT-1401, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
7
States / cities
Birmingham, Alabama • Miami, Florida • Pinellas Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01224015
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions
normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U
Drug · Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

NCT01189747
View directory record Official record
Conditions
Lateral Canthus Rhytides, Crow's Feet Lines
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines, LCL-208

NCT03839693
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
botulinum toxin, Type A, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Pinellas Park, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
Other · Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00907387
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
RT001, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines

NCT03326856
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
botulinum toxin, Type A, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

NCT04259086
View directory record Official record
Conditions
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Interventions
DaxibotulinumtoxinA for injection
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Manhattan Beach, California • San Diego, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 25, 2026, 2:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Collagen Injections for the Treatment of Acne Scars and Wrinkles

NCT01704209
View directory record Official record
Conditions
Acne Scars, Wrinkles
Interventions
Fibroblast Treatment, Vehicle
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines, LCL-209

NCT03912805
View directory record Official record
Conditions
Lateral Canthal Lines, LCL, Crow's Feet
Interventions
botulinum toxin, Type A, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Pinellas Park, Florida • Yardley, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 25, 2026, 2:23 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Improvement in the Appearance of Periorbital Wrinkles

NCT05082766
View directory record Official record
Conditions
Periorbital Wrinkles
Interventions
enhanced DefenAge 8-in-1 BioSerum
Drug
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
31 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

NCT03655691
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
Vehicle, botulinum toxin, Type A
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01064518
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo (Dose B)
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Finding Study In Subjects With Crow's Feet

NCT01951742
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
ANT-1401, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01189760
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions
onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00888914
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001, Vehicle Comparator
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Francisco, California • New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01776606
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 25, 2026, 2:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968825
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 25, 2026, 2:23 AM EDT